GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2012

Celgene Drug Improves PFS in Phase III Melanoma Study

  • Phase III trial data have demonstrated that therapy using Celgene’s Abraxane (paclitaxel protein-bound particles for injectable suspension; albumin-bound).leads to longer progression-free survival (PFS) in chemotherapy-naive metastatic melanoma patients than dacarbazine chemotherapy. PFS among patients given Abraxane reached 4.8 months, compared with 2.5 months for dacarbazine-treated patients. An interim analysis of overall survival (the secondary endpoint) in the open-label CA033 study showed a trend in favor of Abraxane therapy.

    Earlier this month FDA cleared Abraxane as first-line combination therapy with carboplatin in patients with locally advanced or metastatic non-small cell lung cancer who aren’t suitable for surgery or radiation therapy. Abraxane is in addition approved in the U.S. for the treatment of metastatic breast cancer either after failure of combination chemotherapy, or when relapse occurs within six months of adjuvant chemotherapy. Development is ongoing for pancreatic, bladder, and ovarian cancers, and for expanded breast cancer indications.

    Celgene separately today reported its results for the third quarter of 2012, which included global Abraxane sales of $106 million, down 6% on the same period in 2011. U.S. sales of Abraxane, at $81 million, were down 14%. International of the drug were, however, up 29%, at $25 million, due both to volume growth and distributor purchasing patterns. Celgene says that U.S. sales of Abraxane in 2011 had been positively impacted by shortages of generic paclitaxel in the U.S.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »